NRx Pharmaceuticals, Inc.
NRXP
$3.37
-$0.10-2.88%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -23.48M | -24.54M | -28.62M | -38.06M | -33.79M |
| Total Depreciation and Amortization | 481.00K | 307.00K | 143.00K | 44.00K | 3.00K |
| Total Amortization of Deferred Charges | 0.00 | 0.00 | 350.00K | 725.00K | 1.25M |
| Total Other Non-Cash Items | 4.41M | 7.57M | 12.61M | 24.83M | 21.19M |
| Change in Net Operating Assets | -1.19M | 1.74M | 1.41M | -35.00K | -559.00K |
| Cash from Operations | -19.77M | -14.93M | -14.11M | -12.50M | -11.91M |
| Capital Expenditure | -897.00K | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -2.38M | -2.38M | -2.38M | -2.56M | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -432.00K | -645.00K | -432.00K | -- | -- |
| Cash from Investing | -3.71M | -3.02M | -2.81M | -2.56M | -- |
| Total Debt Issued | 237.00K | 5.23M | 5.23M | 9.37M | 12.53M |
| Total Debt Repaid | -204.00K | -228.00K | -548.00K | -4.17M | -6.81M |
| Issuance of Common Stock | 26.93M | 6.21M | 14.47M | 14.47M | 8.47M |
| Repurchase of Common Stock | -- | -5.00M | -5.00M | -5.00M | -5.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 20.30M | 12.90M | 9.13M | 5.93M | 3.73M |
| Cash from Financing | 47.26M | 19.12M | 23.28M | 20.60M | 12.92M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 23.78M | 1.17M | 6.35M | 5.54M | 1.01M |